Tesamorelin
-22%
4X Tested - ISO 17025
99.34% View COA
Growth Peptide

Tesamorelin

Certificate of Analysis

Tesamorelin is a synthetic 44-amino acid GHRH analog that stimulates pulsatile growth hormone release, FDA-approved for HIV-associated lipodystrophy and studied for its metabolic and body composition effects.

BUNDLE & SAVE
2-Day Shipping

Free Shipping
over $200

Free shipment
protection

Secure Checkout
256-bit SSL

Description

What is Tesamorelin?

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of 44 amino acids with a trans-3-hexenoic acid modification at the N-terminus. Tesamorelin is the only GHRH analog that has received FDA approval.

Tesamorelin was approved by the FDA in 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It works by stimulating the pituitary gland to produce and release growth hormone in a pulsatile, physiological manner.

Beyond its approved indication, tesamorelin has been studied for effects on visceral adiposity, cognitive function in aging populations, liver fat reduction, and metabolic parameters. It is unique among GH-related peptides in having a completed regulatory pathway.

Research-grade tesamorelin is not equivalent to FDA-approved version and is sold strictly for laboratory and research purposes only.

Research Applications

Areas of Investigation
Fat Reduction

Visceral Fat Reduction

FDA-approved for reducing excess abdominal fat in HIV-associated lipodystrophy. Studied for broader visceral adiposity reduction.
GH Release

Growth Hormone Axis

Stimulates pulsatile, physiological GH release from the pituitary through GHRH receptor activation, preserving natural feedback mechanisms.
Brain Health

Cognitive Research

Investigated in clinical studies (COGNIS trial) for potential cognitive benefits in aging populations through GH/IGF-1 pathway modulation.
Liver Health

Liver Fat Research

Studied for its effects on hepatic fat reduction and metabolic parameters in patients with non-alcoholic fatty liver disease.

Compound Profile

Technical specifications
What is Tesamorelin?

Molecular Profile

Sequence
hex-YADAIFTNS SYRKVLGQLSA RKLLDQIMSRQ QGESNQER GARARL-NH₂
Molecular Formula
C₂₂₁H₃₆₆N₇₂O₆₇S₁
Molecular Weight
5,135.93 g/mol
Appearance
White lyophilized powder

Form

Lyophilized (freeze-dried)
Handling & Shelf Life Guidelines

Storage & Stability

Storage (Pre-Reconstitution)

Store below -18°C, desiccated, away from light and moisture.
Storage (Post-Reconstitution)
Refrigerate at 2–8°C. For longer storage, aliquot and store below -18°C. Avoid freeze-thaw cycles.
Shelf Life
24 months from date of manufacture when stored as directed
Sensitivity Notes
Sensitive to heat, light, and moisture. Contains methionine susceptible to oxidation. Keep sealed until use.
Compliance & Clinical Overview

Regulatory & Research Status

FDA Status
FDA-approved under a brand name for HIV-associated lipodystrophy. Research-grade peptide is not equivalent to approved formulation.
WADA Classification
Prohibited under class S2 (Peptide Hormones, Growth Factors).
Clinical Trial Status
Extensive clinical and preclinical data on visceral fat reduction, GH/IGF-1 axis, cognitive outcomes, and liver fat.
Published Studies
Extensive clinical and preclinical data on visceral fat reduction, GH/IGF-1 axis, cognitive outcomes, and liver fat.
Research Disclaimer
Research-grade product is for laboratory purposes only. Not equivalent to FDA-approved Egrifta. Not intended for human consumption.

COA's (Certificate of Analysis)

Third Party Tested by Freedom Diagnostics
99.34%
Purity
Variant
Tesamorelin
Lot #
GL-2609-039
Labelled
10mg
Actual
10.21mg
Tested
9/21/2026
View COA
(opens in a new tab)
99.82%
Purity
Variant
Tesamorelin
Lot #
GL-2609-040
Labelled
20mg
Actual
21.13mg
Tested
9/21/2026
View COA
(opens in a new tab)
99.15%
Purity
Variant
Tesamorelin
Lot #
TESA10-GL01
Labelled
10mg
Actual
10.28mg
Tested
6/24/2026
View COA
(opens in a new tab)
99.43%
Purity
Variant
Tesamorelin
Lot #
TESA20-GL01
Labelled
20mg
Actual
20.62mg
Tested
6/24/2026
View COA
(opens in a new tab)

Frequently Asked Questions

Common questions about Tesamorelin research